RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA

Summary by AI BETAClose X

Recordati has announced a strategic collaboration with Moderna to develop and commercialize mRNA-3927 for propionic acidemia, an investigational treatment for a rare metabolic disorder. Under the agreement, Recordati will pay Moderna USD 50 million upfront and up to USD 110 million in near-term development and regulatory milestones, with potential for further commercial milestones and royalties. Moderna will lead development, while Recordati will handle global commercialization if approved. Interim clinical data has shown early signs of improvement, and a potential registrational study has reached target enrollment with data readout expected by the end of 2026. This collaboration strengthens Recordati's rare metabolic portfolio and is not expected to significantly impact EBITDA prior to a potential launch.

Disclaimer*

UK 100

Latest directors dealings